CAMP4 THERAPEUTICS CORPORATION (CAMP)vsVertex Pharmaceuticals Inc (VRTX)

CAMP

CAMP4 THERAPEUTICS CORPORATION

NASDAQ

$4.11

-4.42%

HEALTHCARE · Cap: $216.53M

VRTX

Vertex Pharmaceuticals Inc

NASDAQ

$446.83

-0.03%

HEALTHCARE · Cap: $107.89B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 310474% more annual revenue ($12.22B vs $3.93M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).

CAMP

Avoid

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.5

Piotroski: 3/9Altman Z: -3.49

VRTX

Strong Buy

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5

Piotroski: 3/9Altman Z: 3.62

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CAMP.

VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAMP2 strengths · Avg: 10.0/10

Revenue GrowthGrowth

50.8%10/10

Revenue surging 50.8% year-over-year

Debt/EquityHealth

0.0710/10

Conservative balance sheet, low leverage

VRTX6 strengths · Avg: 9.7/10

Profit MarginProfitability

35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability

38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth

61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth

3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality

$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability

22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

CAMP4 concerns · Avg: 3.3/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$216.53M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

VRTX3 concerns · Avg: 3.7/10

PEG RatioValuation

1.654/10

Expensive relative to growth rate

P/E RatioValuation

25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CAMP

The strongest argument for CAMP centers on Revenue Growth, Debt/Equity. Revenue growth of 50.8% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : CAMP

The primary concerns for CAMP are EPS Growth, Market Cap, Profit Margin.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CAMP profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

CAMP is growing revenue faster at 50.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (68/100 vs 29/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CAMP4 THERAPEUTICS CORPORATION

HEALTHCARE · BIOTECHNOLOGY · USA

CalAmp Corp. The company is headquartered in Irvine, California.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Compare with Other BIOTECHNOLOGY Stocks

CAMP vs REGN CAMP vs ARGX CAMP vs ALNY CAMP vs RVMD CAMP vs RPRX VRTX vs REGN VRTX vs ARGX VRTX vs ALNY VRTX vs RVMD VRTX vs RPRX

Want to dig deeper into these stocks?

Full CAMP Analysis →Full VRTX Analysis →